Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A method of forming cured microparticles includes providing a poly(glycerol sebacate) resin in an uncured state. The method also includes forming the composition into a plurality of uncured microparticles and curing the uncured microparticles to form the plurality of cured microparticles. The uncured microparticles are free of a photo-induced crosslinker. A method of forming a scaffold includes providing microparticles including poly(glycerol sebacate) in a three-dimensional arrangement. The method also includes stimulating the microparticles in the three-dimensional arrangement to sinter the microparticles, thereby forming the scaffold having a plurality of pores. A scaffold is formed of a plurality of microparticles including a poly(glycerol sebacate) thermoset resin in a three-dimensional arrangement. The scaffold has a plurality of pores.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A biocontainment vessel includes a vessel structure including a structural composition and an enhancement composition associated with the structural composition. The enhancement composition includes a co-polymer. The co-polymer is a poly(glycerol sebacate) or a poly(glycerol sebacate urethane). The enhancement composition may also include an augmentation agent associated with the co-polymer. The enhancement composition is located with respect to the structural composition such that the enhancement composition benefits biological cells contained in the biocontainment vessel. A composition includes a co-polymer and an augmentation agent contained by the co-polymer. A method of containing biological cells includes placing the biological cells in an augmented biocontainment vessel and storing them in the augmented biocontainment vessel under predetermined conditions. An augmented substrate includes a substrate and an enhancement composition coating a surface of the substrate.

Abstract: A biocontainment vessel includes a vessel structure including a structural composition and an enhancement composition associated with the structural composition. The enhancement composition includes a co-polymer. The co-polymer is a poly(glycerol sebacate) or a poly(glycerol sebacate urethane). The enhancement composition may also include an augmentation agent associated with the co-polymer. The enhancement composition is located with respect to the structural composition such that the enhancement composition benefits biological cells contained in the biocontainment vessel. A composition includes a co-polymer and an augmentation agent contained by the co-polymer. A method of containing biological cells includes placing the biological cells in an augmented biocontainment vessel and storing them in the augmented biocontainment vessel under predetermined conditions. An augmented substrate includes a substrate and an enhancement composition coating a surface of the substrate.

Abstract: A pH-modulating poly(glycerol sebacate) composition includes poly(glycerol sebacate) and at least one pH-modulating agent associated with the poly(glycerol sebacate). A process of making a pH-modulating poly(glycerol sebacate) composition includes forming a poly(glycerol sebacate) by a water-mediated reaction from glycerol and sebacic acid and associating at least one pH-modulating agent with the poly(glycerol sebacate). A process of modulating a pH of a buffered aqueous solution includes placing a pH-modulating poly(glycerol sebacate) composition in a buffered aqueous solution. The pH-modulating agent is released into the buffered aqueous solution during degradation of the poly(glycerol sebacate) to reduce a decrease in pH of the buffered aqueous solution caused by degradation of the poly(glycerol sebacate).

Abstract: A pH-modulating poly(glycerol sebacate) composition includes poly(glycerol sebacate) and at least one pH-modulating agent associated with the poly(glycerol sebacate). A process of making a pH-modulating poly(glycerol sebacate) composition includes forming a poly(glycerol sebacate) by a water-mediated reaction from glycerol and sebacic acid and associating at least one pH-modulating agent with the poly(glycerol sebacate). A process of modulating a pH of a buffered aqueous solution includes placing a pH-modulating poly(glycerol sebacate) composition in a buffered aqueous solution. The pH-modulating agent is released into the buffered aqueous solution during degradation of the poly(glycerol sebacate) to reduce a decrease in pH of the buffered aqueous solution caused by degradation of the poly(glycerol sebacate).

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A bone filling composition includes a bone filler. The bone filler includes microparticles of at least one elastomeric material. The at least one elastomeric material includes a poly(glycerol sebacate)-based thermoset. The poly(glycerol sebacate)-based thermoset may be porous thermoset poly(glycerol sebacate) flour, thermoset poly(glycerol sebacate) microspheres, or a combination thereof. In some embodiments, the bone filling composition is a bone filling composite that further includes a carrier material including a poly(glycerol sebacate) resin. A method of forming a bone filling composite includes selecting a bone filler and mixing the bone filler with a carrier material to form the bone filling composite. A method of treating a bony defect includes molding a bone filling composite and placing the bone filling composite in the bony defect. The bone filling composite includes a bone filler mixed with a carrier material.

Abstract: A method of forming a skin care product includes combining at least one additive including at least one active ingredient with at least one glycerol-sebacate component having repeating units of (glycerol sebacate), water, a co-solvent, and at least one of an emulsifier, a surfactant, and a bodying agent to form the skin care product. A dermocosmetic composition includes at least one additive including at least one active ingredient and at least one glycerol-sebacate component having repeating units of (glycerol sebacate). A method of skin care includes applying a dermocosmetic composition to a skin surface.

Abstract: A method of forming a skin care product includes combining at least one additive including at least one active ingredient with at least one glycerol-sebacate component having repeating units of (glycerol sebacate), water, a co-solvent, and at least one of an emulsifier, a surfactant, and a bodying agent to form the skin care product. A dermocosmetic composition includes at least one additive including at least one active ingredient and at least one glycerol-sebacate component having repeating units of (glycerol sebacate). A method of skin care includes applying a dermocosmetic composition to a skin surface.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A bone filling composition includes a bone filler. The bone filler includes microparticles of at least one elastomeric material. The at least one elastomeric material includes a poly(glycerol sebacate)-based thermoset. The poly(glycerol sebacate)-based thermoset may be porous thermoset poly(glycerol sebacate) flour, thermoset poly(glycerol sebacate) microspheres, or a combination thereof. In some embodiments, the bone filling composition is a bone filling composite that further includes a carrier material including a poly(glycerol sebacate) resin. A method of forming a bone filling composite includes selecting a bone filler and mixing the bone filler with a carrier material to form the bone filling composite. A method of treating a bony defect includes molding a bone filling composite and placing the bone filling composite in the bony defect. The bone filling composite includes a bone filler mixed with a carrier material.

Abstract: A method includes combining an alcohol-pharmaceutical conjugate, a polyol, and an aqueous liquid in a vessel. The alcohol-pharmaceutical conjugate includes a pharmaceutical compound having at least one carboxyl group attached to the polyol by an ester bond. The method also includes adding an acid monomer to the vessel and heating and removing water from the vessel to produce the polymeric material. The polymeric material includes a polyester copolymer of the acid monomer and the polyol and the pharmaceutical compound.

Abstract: The application is directed to aqueous dispersible biodegradable compositions of esters which are the condensation reaction product of a polyol and a diacid which are within a matrix of hydrated polypeptide. The compositions are useful in additive manufacturing and other applications for use with implantable articles. In some embodiments, the ester in the compositions is the product of a glyercol-sebacic acid condensation reaction.

Abstract: A method of preparing a polymeric material includes combining a glycerol-pharmaceutical conjugate, glycerol, and water in a vessel. The glycerol-pharmaceutical conjugate includes a pharmaceutical compound, for example, salicylic acid, having at least one carboxyl group attached to glycerol by an ester bond. The method also includes adding sebacic acid to the vessel and removing water from the vessel and reacting the glycerol, glycerol-pharmaceutical conjugate, and sebacic acid in the vessel at atmospheric pressure in the presence of an inert gas. The method further includes applying a sub-atmospheric pressure to the vessel after the step of reacting, to form the polymeric material in the vessel. The polymeric material includes a polyester copolymer of the sebacic acid and the glycerol and the pharmaceutical compound.

Abstract: The application is directed to aqueous dispersible biodegradable compositions of esters which are the condensation reaction product of a polyol and a diacid which are within a matrix of hydrated polypeptide. The compositions are useful in additive manufacturing and other applications for use with implantable articles. In some embodiments, the ester in the compositions is the product of a glyercol-sebacic acid condensation reaction.

Abstract: A method of forming cured microparticles includes providing a poly(glycerol sebacate) resin in an uncured state. The method also includes forming the composition into a plurality of uncured microparticles and curing the uncured microparticles to form the plurality of cured microparticles. The uncured microparticles are free of a photo-induced crosslinker. A method of forming a scaffold includes providing microparticles including poly(glycerol sebacate) in a three-dimensional arrangement. The method also includes stimulating the microparticles in the three-dimensional arrangement to sinter the microparticles, thereby forming the scaffold having a plurality of pores. A scaffold is formed of a plurality of microparticles including a poly(glycerol sebacate) thermoset resin in a three-dimensional arrangement. The scaffold has a plurality of pores.

Abstract: A filler material of a thermoset resin of a diacid/polyol, such as PGS is provided. The filler useful in forming composites, such as those in which the filler and a resin matrix are of the same material to provide a homogenous polymeric composition. Composites in which at least one of the matrix, the filler or both are PGS are also provided. Methods of forming such filler materials and composites are also disclosed. The composites allow extrusion process to form articles from materials that would not otherwise be capable of being extruded.